Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/56185
Tipo
ArtículoDerechos de autor
Acceso abierto
Colecciones
- IOC - Artigos de Periódicos [12642]
- PR - ICC - Artigos de Periódicos [659]
Metadatos
Mostrar el registro completo del ítem
LESSONS FROM THE PANDEMIC: RESPONDING TO EMERGING ZOONOTIC VIRAL DISEASES—A KEYSTONE SYMPOSIA REPORT
Communicable Diseases
Infectious Diseases
Lassa virus
Nipah Virus
Vaccines
Zoonotic Diseases
Ebolavirus
Doenças Transmissíveis
Doenças Infecciosas
Vírus Lassa
Vírus Nipah
Vacinas
Zoonoses
Autor
Cable, Jennifer
Fauci, Anthony
Dowling, William E.
Günther, Stephan
Bente, Dennis A.
Yadav, Pragya Dhruv
Madoff, Lawrence C.
Wang, Lin-Fa
Arora, Rahul K.
Kerkhove, Maria Van
Chu, May C.
Jaenisch, Thomas
Epstein, Jonathan H.
Frost, Simon David William
Bausch, Daniel G.
Hensley, Lisa E.
Bergeron, Éric
Sitaras, Ioannis
Gunn, Michael D.
Geisbert, Thomas W.
Muñoz-Fontela, César
Krammer, Florian
Wit, Emmie de
Nordenfelt, Pontus
Saphire, Erica Ollmann
Gilbert, Sarah C.
Corbett, Kizzmekia S.
Branco, Luis M.
Baize, Sylvain
Doremalen, Neeltje van
Krieger, Marco Aurelio
Clemens, Sue Ann Costa
Hesselink, Renske
Hartman, Dan
Fauci, Anthony
Dowling, William E.
Günther, Stephan
Bente, Dennis A.
Yadav, Pragya Dhruv
Madoff, Lawrence C.
Wang, Lin-Fa
Arora, Rahul K.
Kerkhove, Maria Van
Chu, May C.
Jaenisch, Thomas
Epstein, Jonathan H.
Frost, Simon David William
Bausch, Daniel G.
Hensley, Lisa E.
Bergeron, Éric
Sitaras, Ioannis
Gunn, Michael D.
Geisbert, Thomas W.
Muñoz-Fontela, César
Krammer, Florian
Wit, Emmie de
Nordenfelt, Pontus
Saphire, Erica Ollmann
Gilbert, Sarah C.
Corbett, Kizzmekia S.
Branco, Luis M.
Baize, Sylvain
Doremalen, Neeltje van
Krieger, Marco Aurelio
Clemens, Sue Ann Costa
Hesselink, Renske
Hartman, Dan
Afiliación
PhD Science Writer. New York, New York, USA.
Laboratory of Immunoregulation. National Institute of Allergy and Infectious Diseases. National Institutes of Health. Bethesda, Maryland, USA.
Coalition for Epidemic Preparedness Innovations. Oslo, Norway.
Bernhard Nocht Institute for Tropical Medicine and German Center for Infection Research. Hamburg, Germany.
University of Texas Medical Branch. Galveston National Laboratory. Galveston, Texas, USA / Division of Biology and Biological Engineering. California Institute of Technology. Pasadena, California, USA.
Indian Council of Medical Research-National Institute of Virology. Pune, India.
Department of Medicine. University of Massachusetts Chan School of Medicine. Worcester, Massachusetts, USA.
Duke-NUS Medical School. Singapore.
Department of Community Health Sciences. University of Calgary. Calgary, Alberta, Canada / Institute of Biomedical Engineering. University of Oxford. Oxford, UK.
World Health Organization. Geneva, Switzerland.
Colorado School of Public Health. Anschutz Medical Campus. Aurora, Colorado, USA.
Colorado School of Public Health. Anschutz Medical Campus. Aurora, Colorado, USA.
Eco Health Alliance. New York, USA.
Microsoft Research. Redmond. Washington, USA.
FIND. The global alliance for diagnostics. Geneva, Switzerland.
Partnership for Research on Vaccines and Infectious Diseases in Liberia. Monrovia, Liberia / Division of Clinical Research. National Institute of Allergy and Infectious Diseases. Bethesda, Maryland, USA.
Viral Special Pathogens Branch. Division of High-Consequence Pathogens and Pathology. Centers for Disease Control and Prevention. Atlanta, Georgia, USA.
W. Harry Feinstone Department of Molecular Microbiology and Immunology. Johns Hopkins Bloomberg School of Public Health. Baltimore, Maryland, USA.
Department of Medicine. Duke University Medical Center. Durham, North Carolina, USA.
University of Manitoba. Winnipeg, Manitoba, Canada / Galveston National Laboratory and Department of Microbiology and Immunology. University of Texas Medical Branch. Galveston, Texas, USA.
Bernhard Nocht Institute for Tropical Medicine and German Center for Infection Research. Hamburg, Germany.
Department of Microbiology and Department of Pathology. Icahn School of Medicine at Mount Sinai. New York, USA.
Laboratory of Virology. Division of Intramural Research. National Institute of Allergy and Infectious Diseases. National Institutes of Health. Hamilton, Montana, USA.
Department of Clinical Sciences Lund. Infection Medicine. Faculty of Medicine. Lund University. Lund, Sweden.
Center for Infectious Disease and Vaccine Research. La Jolla Institute for Immunology. La Jolla, California, USA.
Pandemic Sciences Institute. Nuffield Department of Medicine. University of Oxford. Oxford, UK.
Department of Immunology and Infectious Diseases. Harvard T.H. Chan School of Public Health. Boston. Massachusetts, USA.
Zalgen Labs. Germantown. Maryland, USA.
Unité de Biologie des Infections Virales Emergentes. Institut Pasteur. Lyon, France / Centre International de Recherche en Infectiologie (CIRI). Lyon, France / INSERM. Ecole Normale Supérieure de Lyon. Université de Lyon. Lyon, France.
Laboratory of Virology. Division of Intramural Research. National Institute of Allergy and Infectious Diseases. National Institutes of Health. Hamilton, Montana, USA.
Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Ciências e Tecnologias Aplicadas em Saúde. Curitiba, PR, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Programa Translacional Integrado de Doença de Chagas da Fiocruz (Fio-Chagas). Rio de Janeiro, RJ, Brasil.
Oxford Vaccine Group. Oxford University. Oxford, UK / Institute for Global Health. University of Siena. Siena, Italy.
Coalition for Epidemic Preparedness Innovations. Oslo, Norway.
Bill & Melinda Gates Foundation. Seattle. Washington, USA.
Laboratory of Immunoregulation. National Institute of Allergy and Infectious Diseases. National Institutes of Health. Bethesda, Maryland, USA.
Coalition for Epidemic Preparedness Innovations. Oslo, Norway.
Bernhard Nocht Institute for Tropical Medicine and German Center for Infection Research. Hamburg, Germany.
University of Texas Medical Branch. Galveston National Laboratory. Galveston, Texas, USA / Division of Biology and Biological Engineering. California Institute of Technology. Pasadena, California, USA.
Indian Council of Medical Research-National Institute of Virology. Pune, India.
Department of Medicine. University of Massachusetts Chan School of Medicine. Worcester, Massachusetts, USA.
Duke-NUS Medical School. Singapore.
Department of Community Health Sciences. University of Calgary. Calgary, Alberta, Canada / Institute of Biomedical Engineering. University of Oxford. Oxford, UK.
World Health Organization. Geneva, Switzerland.
Colorado School of Public Health. Anschutz Medical Campus. Aurora, Colorado, USA.
Colorado School of Public Health. Anschutz Medical Campus. Aurora, Colorado, USA.
Eco Health Alliance. New York, USA.
Microsoft Research. Redmond. Washington, USA.
FIND. The global alliance for diagnostics. Geneva, Switzerland.
Partnership for Research on Vaccines and Infectious Diseases in Liberia. Monrovia, Liberia / Division of Clinical Research. National Institute of Allergy and Infectious Diseases. Bethesda, Maryland, USA.
Viral Special Pathogens Branch. Division of High-Consequence Pathogens and Pathology. Centers for Disease Control and Prevention. Atlanta, Georgia, USA.
W. Harry Feinstone Department of Molecular Microbiology and Immunology. Johns Hopkins Bloomberg School of Public Health. Baltimore, Maryland, USA.
Department of Medicine. Duke University Medical Center. Durham, North Carolina, USA.
University of Manitoba. Winnipeg, Manitoba, Canada / Galveston National Laboratory and Department of Microbiology and Immunology. University of Texas Medical Branch. Galveston, Texas, USA.
Bernhard Nocht Institute for Tropical Medicine and German Center for Infection Research. Hamburg, Germany.
Department of Microbiology and Department of Pathology. Icahn School of Medicine at Mount Sinai. New York, USA.
Laboratory of Virology. Division of Intramural Research. National Institute of Allergy and Infectious Diseases. National Institutes of Health. Hamilton, Montana, USA.
Department of Clinical Sciences Lund. Infection Medicine. Faculty of Medicine. Lund University. Lund, Sweden.
Center for Infectious Disease and Vaccine Research. La Jolla Institute for Immunology. La Jolla, California, USA.
Pandemic Sciences Institute. Nuffield Department of Medicine. University of Oxford. Oxford, UK.
Department of Immunology and Infectious Diseases. Harvard T.H. Chan School of Public Health. Boston. Massachusetts, USA.
Zalgen Labs. Germantown. Maryland, USA.
Unité de Biologie des Infections Virales Emergentes. Institut Pasteur. Lyon, France / Centre International de Recherche en Infectiologie (CIRI). Lyon, France / INSERM. Ecole Normale Supérieure de Lyon. Université de Lyon. Lyon, France.
Laboratory of Virology. Division of Intramural Research. National Institute of Allergy and Infectious Diseases. National Institutes of Health. Hamilton, Montana, USA.
Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Ciências e Tecnologias Aplicadas em Saúde. Curitiba, PR, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Programa Translacional Integrado de Doença de Chagas da Fiocruz (Fio-Chagas). Rio de Janeiro, RJ, Brasil.
Oxford Vaccine Group. Oxford University. Oxford, UK / Institute for Global Health. University of Siena. Siena, Italy.
Coalition for Epidemic Preparedness Innovations. Oslo, Norway.
Bill & Melinda Gates Foundation. Seattle. Washington, USA.
Resumen en ingles
The COVID-19 pandemic caught the world largely unprepared, including scientific and policy communities. On April 10–13, 2022, researchers across academia, industry, government, and nonprofit organizations met at the Keystone symposium “Lessons from the Pandemic: Responding to Emerging Zoonotic Viral Diseases” to discuss the successes and challenges of the COVID-19 pandemic and what lessons can be applied moving forward. Speakers focused on experiences not only from the COVID-19 pandemic but also from outbreaks of other pathogens, including the Ebola virus, Lassa virus, and Nipah virus. A general consensus was that investments made during the COVID-19 pandemic in infrastructure, collaborations, laboratory and manufacturing capacity, diagnostics, clinical trial networks, and regulatory enhancements—notably, in low-to-middle income countries—must be maintained and strengthened to enable quick, concerted responses to future threats, especially to zoonotic pathogens.
Palabras clave en ingles
EbolavirusCommunicable Diseases
Infectious Diseases
Lassa virus
Nipah Virus
Vaccines
Zoonotic Diseases
DeCS
COVID-19Ebolavirus
Doenças Transmissíveis
Doenças Infecciosas
Vírus Lassa
Vírus Nipah
Vacinas
Zoonoses
Compartir